1. Clinical Overview of Larazotide
Molecule: Larazotide Acetate (AT-1001) · Class: Tight Junction Regulator / Zonulin Pathway Antagonist / Anti-inflammatory Peptide
Clinical Orientation: Larazotide is an orally active peptide that regulates tight junctions in the gastrointestinal epithelium. Initially developed for celiac disease, it has broad clinical relevance for conditions characterized by increased intestinal permeability. By antagonizing zonulin signaling and restoring epithelial integrity, Larazotide is explored for:
- Reduction of intestinal permeability ("leaky gut")
- Downregulation of systemic and gut-associated inflammation
- Prevention of antigenic and microbial translocation
- Adjunctive treatment for autoimmune, neurologic, dermatologic, and metabolic disorders linked to GI barrier dysfunction
2. Mechanisms of Action
2.1 Zonulin Pathway Antagonism
Zonulin modulates tight junction permeability. Elevated zonulin signaling contributes to tight junction disassembly, increased intestinal permeability, translocation of antigens/endotoxins (LPS)/pathogens, systemic inflammation, and autoimmune disease progression. Larazotide antagonizes zonulin-mediated signaling.
2.2 Barrier Restoration
Clinical benefits: Enhanced intestinal epithelial barrier integrity · Prevention of claudin and occludin protein disassembly · Reduced paracellular permeability · Restored mucosal homeostasis
Barrier restoration prevents endotoxin (LPS) passage into systemic circulation, antigenic protein translocation, microbial/pathogen entry, and immune system activation from gut-derived signals.
2.3 Anti-Inflammatory Actions
Reduced translocation produces: downregulated pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), decreased systemic inflammation, reduced autoimmune trigger activation, improved gut-brain, gut-skin, and gut-immune axis homeostasis.
2.4 Key Advantage
No Systemic Immunosuppression: Larazotide works locally in the GI tract without systemic hormonal or immunosuppressive activity, making it well-suited for long-term adjunctive use in chronic conditions.
2.5 Synergy With Other Peptides
With BPC-157: Larazotide restores tight junctions → BPC-157 promotes mucosal healing. Comprehensive gut barrier repair with synergistic anti-inflammatory action.
With KPV: KPV provides NF-κB inhibition and cytokine modulation while Larazotide addresses barrier dysfunction. Dual-mechanism inflammation control.
With Glutathione / NAD+: Redox support for gut lining oxidative stress with enhanced cellular repair alongside barrier restoration.
3. Evidence Summary — Clinical Domains
3.1 Gastrointestinal Conditions
- Increased Intestinal Permeability / "Leaky Gut": Primary indication with direct mechanistic targeting
- Celiac Disease & Gluten Sensitivity: Prevents gluten-triggered tight junction disruption
- IBS (Irritable Bowel Syndrome): Addresses permeability component of symptoms
- IBD (Crohn's, Ulcerative Colitis): Adjunctive barrier support for inflammatory bowel conditions
3.2 Autoimmune & Systemic Conditions
- Autoimmune Diseases: Rheumatoid arthritis, Hashimoto's thyroiditis, lupus, MS with gut-immune axis involvement
- Chronic Fatigue Syndrome: Addresses systemic inflammation linked to barrier dysfunction
- Fibromyalgia: Inflammatory component management
3.3 Neuroinflammation & Gut-Brain Axis
Brain fog and cognitive symptoms, mood disorders linked to gut permeability, neuroinflammatory conditions. Integrates well with Semax/Selank for neuroplasticity, BPC-157 for gut-brain axis support, NAD+ for cellular energetics.
3.4 Dermatologic & Metabolic Conditions
Psoriasis, eczema, acne with gut-skin axis involvement. Metabolic dysfunction: insulin resistance and metabolic syndrome with inflammatory components.
4. Administration Routes & Protocols
4.1 Route of Administration
Submucosal Oral (preferred): Swish and hold 60–90 seconds before swallowing
Sublingual: Hold under tongue for enhanced absorption through oral mucosa
Transnasal: Nasal spray delivery as alternative route for mucosal absorption
4.2 Reconstitution (5 mg Lyophilized Vial)
Diluent: 2 mL sterile bacteriostatic saline · Method: Gently swirl until dissolved — do NOT shake
Final Concentration: 2.5 mg/mL (0.1 mL = 0.25 mg; 0.4 mL = 1 mg)
Storage: Refrigerate (2–8°C) — use within 7–10 days
4.3 Typical Dosing
Initial Dose: 0.5 mg to 1 mg per administration · Frequency: 1–2× daily
Method: Draw 0.2–0.4 mL, swish and hold for 60–90 seconds
Timing: 15–30 minutes before meals · Cycle: 6–8 weeks on, 2–4 weeks off
5. Clinical Decision Trees
Decision Tree 1 — Protocol Selection
Leaky gut / elevated zonulin confirmed? → Larazotide 0.5–1 mg 2× daily × 6–8 weeks
Celiac / gluten sensitivity? → Larazotide 0.5 mg before meals + strict GFD
IBS/IBD with barrier dysfunction? → Larazotide + BPC-157 + KPV stack × 6–8 weeks
Autoimmune with gut-immune axis involvement? → Larazotide + immune support × 8 weeks, reassess
Neuroinflammation / brain fog? → Larazotide + Semax/Selank + BPC-157
Decision Tree 2 — Larazotide vs BPC-157 vs KPV
Primary barrier dysfunction / permeability? → Larazotide
Primary mucosal injury / ulceration? → BPC-157
Primary immune-mediated GI inflammation? → KPV
Mixed barrier + inflammation? → Larazotide + KPV
Comprehensive gut repair? → Larazotide + BPC-157 + KPV
6. Integrated Treatment Archetypes
Archetype A — Comprehensive Gut Repair
Systemic: Larazotide 0.5–1 mg 1–2× daily + BPC-157 250–500 mcg oral/SC daily + KPV 200–500 mcg oral daily
Outcome: Comprehensive gut barrier restoration with multi-pathway support.
Archetype B — Autoimmune Support
Systemic: Larazotide 1 mg 2× daily + Thymosin Alpha-1 per immune protocol + Glutathione 200–500 mg daily
Lifestyle: Anti-inflammatory diet, stress management, sleep optimization
Archetype C — Gut-Brain Axis
Systemic: Larazotide 0.5–1 mg daily + BPC-157 250 mcg SC daily + Semax or Selank per neuroplasticity protocol + NAD+ weekly
Outcome: Improved cognitive clarity, reduced neuroinflammation, enhanced gut-brain communication.
Archetype D — Post-Antibiotic / Dysbiosis Recovery
Systemic: Larazotide 0.5 mg 2× daily + BPC-157 250 mcg oral daily + KPV 250 mcg oral daily
Adjuncts: Probiotics, prebiotic fiber, bone broth
7. Expected Clinical Timeline
Week 1–2: Initial GI symptom improvement, reduced bloating
Week 3–4: Decreased inflammatory markers, improved digestion
Week 6–8: Measurable barrier restoration, autoimmune flare reduction
8. Contraindications, Adverse Effects & Monitoring
Contraindications
- Active GI ulceration (theoretical caution)
- Severely immunocompromised patients (limited data)
- Pregnancy / lactation (insufficient data)
- Known hypersensitivity to peptide components
Safety Profile
Clinical trials have demonstrated safety at doses up to 12 mg/day orally with minimal adverse effects. No systemic hormonal or immunosuppressive activity. Local GI action with minimal systemic absorption.
Monitoring
- GI symptom tracking (bloating, discomfort, bowel patterns)
- Zonulin levels (if available)
- Inflammatory markers (CRP, ESR)
- Autoimmune disease activity markers
- Subjective well-being and energy levels
Legal Disclaimer
This document is provided solely for educational and informational purposes. Larazotide (AT-1001) and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use. Peptide Protocol Portal makes no representations or warranties. Clinical decisions remain the sole responsibility of the licensed practitioner. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable for any damages or adverse outcomes. Use at your own risk.
References — Larazotide Acetate (AT-1001) Clinical Reference Guide
Clinical Trials & Efficacy
1. Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology, 148(7), 1311-1319 (2015).
2. Kelly CP, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Alimentary Pharmacology & Therapeutics, 37(2), 252-262 (2013).
3. Paterson BM, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Alimentary Pharmacology & Therapeutics, 26(5), 757-766 (2007).
Zonulin & Intestinal Permeability
4. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiological Reviews, 91(1), 151-175 (2012).
5. Lammers KM, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology, 135(1), 194-204 (2008).